Markets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
All Features
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
F&O
Financials
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Price History/Seasonality
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
Alerts
About
Divi's Laboratories Ltd.
NSE: DIVISLAB
|
BSE: 532488
|
ISIN: INE361B01024
|
Industry: Pharmaceuticals
|
Expensive Star
6616.5000
16.00
(
0.24
%)
NSE
Jan 09, 2026
15:31 PM
33.53% Gain from 52W Low
Volume:
351.0K
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Divi's Laboratories Ltd.
07 Nov 2020
6616.50
0.24%
Divi's Labs (ADD): Flawless execution drives Q2 beat upgrade to ADD
Accumulate:
Divi's Laboratories Ltd.
by
BOB Capital Markets Ltd.
Target: 3520
Recommendation
Target
BOB Capital Markets Ltd.
Divi's Labs (DIVI) retained its strong execution in Q2, reporting an 18% EBITDA beat.
Divi's Laboratories Ltd. is trading above all available SMAs
More from Divi's Laboratories Ltd.
Recommended
Five Interesting Stocks Today - January 9, 2026
The Baseline |
09 Jan 2026
Market closes lower, dragged down by foreign investor outflows and rising crude prices
Trendlyne Marketwatch |
09 Jan 2026
Custom synthesis business drives growth for Divi’s Laboratories
|
10 Mar 2022, 06:14AM